WAHT- TWI Guidelines for Osteoporosis in Worcestershire.
|
|
- Myron Harvey
- 6 years ago
- Views:
Transcription
1 GUIDELINES FOR OSTEOPOROSIS IN WORCESTERSHIRE This guidance does not override the individual responsibility of health professionals to make appropriate decisions according to the circumstances of the individual patient in consultation with the patient and /or carer. Health care professionals must be prepared to justify any deviation from this guidance. INTRODUCTION 3 million people in UK have osteoporosis Almost half of the 10.6 million women aged over 50 in the UK will break a bone during their lifetime, mainly due to osteoporosis Only 480,000 women on bone fracture prevention 1 in 5 men will fracture a bone after the age of 50 A progressive systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture (WHO 1994) i.e. a BMD T-score of -2.5 SD or below peak BMD (BMD for a young adult.) A skeletal disorder characterised by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength is dependent on Bone Density in g/cm 2 and bone architecture quality which is influenced by bone architecture, bone turnover and damage accumulation (NIH Consensus Development Panel on Osteoporosis JAMA 285 (2001) ). (A 10-year risk of fracture model has been developed to identify those at highest risk. See guideline. ( More information is available on the Map of Medicine for Osteoporosis via the Worcestershire Health Libraries website: THIS GUIDELINE IS FOR USE BY THE FOLLOWING STAFF GROUPS: All staff groups in primary and secondary care in Worcestershire involved in the treatment of patients with osteoporosis and osteoporotic fragility fracture(s) or at risk of developing osteoporosis or osteoporotic fragility fracture(s). Osteoporosis Specialist Nurse. See guideline for details of patient groups. Lead Clinicians Dr R Dutta Dr A Rai Mrs R Hodkinson Consultant Physician Elderly Care Consultant Physician Rheumatology Lead Clinical Pharmacist Trauma and Orthopaedics (WRH) Approved by Medicines Safety Committee on: 20 May 2008 Approved by Area Prescribing Committee on: Additional guidance approved for Denosumab 3 April August 2011 This guideline should not be used after end of: April 2014 Worcestershire Acute Hospitals NHS Trust Page 1 of 35
2 THIS DOCUMENT MUST NOT BE PHOTOCOPIED If you require a copy for your ward / department, please contact the Clinical Effectiveness Department on PLEASE NOTE THAT ALL CLINICAL GUIDELINES / PROTOCOLS / POLICIES ARE ALSO AVAILABLE ON THE TRUST INTRANET Worcestershire Acute Hospitals NHS Trust Page 2 of 35
3 CONTENTS GUIDELINES FOR OSTEOPOROSIS FOR WORCESTERSHIRE.. 1 INTRODUCTION 1 To be used by the following staff groups 1 Lead clinicians. 1 Approval dates 1 Contents.. 3 Introduction... 5 Who to scan (including clinical risk factors)... 6 Treatment: life styles changes Lifestyle advice. 8 2 Assess the risk of falls. 8 3 Calcium and vitamin D 8 4 Exercises. 8 General principles of primary prevention of osteoporotic fragility fracture(s) in women...9 Treatment: Which drug First-line Second-line Third-line or if intolerant of bisphosphonates or contraindicated. 10 Secondary prevention/treatment of osteoporotic fragility fracture(s) in women Treatment: Which drug First-line Second-line Third-line or if intolerant of bisphosphonates or contraindicated Alternatives if both bisphosphonates and Strontium cannot be taken.13 Cautions, relative and absolute contraindications that affect choice of treatment 15 Other factors that affect choice of treatment...16 Men with osteoporosis Outcome measures Monitoring tool References Appendix 1 Breast cancer patients Appendix 2 Bowel disease patients Appendix 3 Corticosteroid therapy Appendix 4A Level 1 Falls Referral Form Appendix 4B Level 3 Specialist Falls Clinic Referral Form Appendix 5 DEXA scan request form Appendix 6 DEXA scan report letter..30 Appendix 7 Quick reference guide to primary prevention of Osteoporotic fragility fracture(s)in Women 31 Quick reference guide to secondary prevention of Osteoporotic fragility fracture(s) in Women. Quick reference guide to Osteoporosis in Men Quick reference guide to Osteoporosis in Breast cancer patients Quick reference guide to Osteoporosis in bowel disease patients Quick reference guide to Osteoporosis in corticosteroid patients..31 Appendix 8 Referral for Osteoporosis Specialist Nurse...32 Worcestershire Acute Hospitals NHS Trust Page 3 of 35
4 Appendix 9 Guidelines for initiating treatment with Denosumab.33 Contribution list Worcestershire Acute Hospitals NHS Trust Page 4 of 35
5 GUIDELINES FOR OSTEOPOROSIS FOR WORCESTERSHIRE INTRODUCTION 3 million people in UK have osteoporosis Almost half of the 10.6 million women aged over 50 in the UK will break a bone during their lifetime, mainly due to osteoporosis Only 480,000 women on bone fracture prevention 1 in 5 men will fracture a bone after the age of 50 A progressive systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture (WHO 1994) i.e. a Bone Mineral Density (BMD) 2.5 Standard Deviations (SD) or more below the young female adult mean (T-score of -2.5 or below). T- score relates to the measurement of bone mineral density (BMD) using central (hip and/or spine) dual-energy X-ray absorptiometry (DEXA) scanning. (NICE technology appraisal guidance 160 and 161, October 2008) A skeletal disorder characterised by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength is dependent on Bone Density in g/cm 2 and bone architecture quality which is influenced by bone architecture, bone turnover and damage accumulation (NIH Consensus Development Panel on Osteoporosis JAMA 285 (2001) ). (A 10-year risk of fracture model has been developed to identify those at highest risk. The FRAX tool ( computes the 10-year probability of hip fracture or a major osteoporotic fracture using a patient s clinical risk factors with or without bone mineral density results. This should be used in combination with a falls risk assessment. NICE are currently developing a guideline to assess the fracture risk). Worcestershire Acute Hospitals NHS Trust Page 5 of 35
6 GUIDELINE WHO TO DEXA SCAN? (Dual energy X-ray absorptiometry DEXA) A 10-year risk of fracture model has been developed to identify those at highest risk. The FRAX tool ( computes the 10-year probability of hip fracture or a major osteoporotic fracture using a patient s clinical risk factors with or without bone mineral density (BMD) results, but see notes below. (NB the tool does not currently include falls in the algorithm and a falls risk assessment should also be carried out) The clinical risk factors (in combination with BMD results) used by the FRAX tool in computing the 10 year fracture risk are: Age Sex BMI Previous fracture Parent fractured hip Current smoking Glucocorticoids (equivalent to Prednisolone 5mg daily or more for more than 3 months) Rheumatoid arthritis Secondary osteoporosis (i.e. the patient has a disorder strongly associated with osteoporosis. These include type I (insulin dependent) diabetes), osteogenesis imperfect in adults, untreated long standing hyperthyroidism, hypogonadism or premature menopause (<45 years), chronic malnutrition, or malabsorption and chronic liver disease. Alcohol 3 or more units per day NICE are also developing a clinical guideline Osteoporosis: assessment of fracture risk and the prevention of osteoporosis fractures in individuals at high risk. Fracture risk should be assessed in postmenopausal women and in men aged 50 years or more: If using the FRAX model: - If using before a BMD is obtained and the patient has a fracture probability above the lower no treatment threshold but below the higher treatment threshold, a DEXA scan should be considered and the fracture risk reassessed once the BMD is known. - If using before a BMD is obtained and the probability obtained is below the lower assessment threshold, the patient can be reassured and reassessed as their clinical risk factors change. - If using before a BMD is obtained and the probability is above the intervention threshold, treatment should be considered without the need for a DEXA scan, although it may be useful to monitor response. If not using the FRAX model, identify patients at risk using definitions provided in NICE TA160 and NICE TA161: Table 1 Indicators of low BMD (column A) Independent clinical risk factors for fracture (column B) Low body mass index (BMI 22kg/m 2 or less) Rheumatoid Arthritis Untreated premature menopause Parental history of hip fracture Prolonged Immobilisation Alcohol intake of 4 units or more daily Ankylosing spondylitis Crohn s disease (see appendix 2) Then for women: Worcestershire Acute Hospitals NHS Trust Page 6 of 35
7 Table 2 Age Risk factors (from table 1) DEXA scan? 75 or older 2 or more Not if clinically inappropriate or unfeasible or more Yes Under 65 years old 2 or more (1 each from Yes columns A&B) In men men are not currently covered in the NICE guidelines but NOGG ( have issued guidelines which include men over the age of 50 see page 16. In addition the following clinical risk factors either increase fracture risk independently of BMD or are associated with low BMD and are therefore secondary causes of osteoporosis and in patients with these risk factors, clinicians will need to assess on a case by case basis who should be referred for a scan (e.g. patients also at risk of falls): Low trauma fracture or vertebral deformity, age less than 75 years Oral steroid therapy, age less than 65 years (see appendix 3) Men and women with primary hypogonadism Premature menopause (age less than 45 years) or prolonged amenorrhoea Untreated menopause Radiographic evidence of osteopenia Chronic disease associated with osteoporosis: - Anorexia Nervosa - Malabsorption - Primary Hyperparathyroidism - Post-transplantation - Chronic Renal Failure - Hyperthyroidism - Cushing s Syndrome Post menopausal women with maternal hip fracture or body mass index (BMI) 19kg/m² or less Other Clinical risk factors to consider: Type I diabetics. Current smokers. Reversible secondary causes of osteoporosis, such as those listed above, should be excluded, in both men and women, before treatment for osteoporosis is initiated. Monitoring therapy In the initial stages of osteoporosis treatment a repeat DEXA scan at months may be considered to assess response, depending on the clinical picture and fracture risk. Worcestershire Acute Hospitals NHS Trust Page 7 of 35
8 ALL PATIENTS Treatment: life styles changes 1. Lifestyle advice diet, stopping smoking and reducing alcohol intake. 2. Assess the risk of falls, particularly in the elderly [Age/Polypharmacy/Cognitive impairment/lack of exercise/vitamin D deficiency]. Refer all patients to the Community Falls Co-ordinator using the Level 1 referral form for a community falls assessment. (See appendix 4a). For complex patients or those with unexplained recurrent falls, use the Level 3 referral form (appendix 4B) to refer to the specialist hospital falls clinic. 3. Calcium and Vitamin D 3 Ensure a daily intake of at least 1g calcium and 800 IU vitamin D daily. Check serum calcium, alkaline phosphatase and occasionally Vitamin D levels (10-60 ng/ml) first. If dietary intake is inadequate, prescribe in a suitable combination preparation. (There is now a range of formulations available to aid compliance and patient tolerability.) Consider Calcium and Vitamin D supplementation in housebound (e.g. care homes), frail, elderly patients at risk of falls. See Guidelines for the use of calcium and vitamin D in falls prevention in adults. Worcestershire County Area Prescribing Committee. The use of anti-resorptive agents e.g. Bisphosphonates, Strontium and Denosumab are contraindicated in patients with hypocalcaemia, therefore ensure any deficiency is corrected before initiating therapy with these agents. 4. Exercises: Bones, like muscles, become weaker if not exercised. Regular weight bearing exercise can improve bone density and reduce fracture risk. (Wolf I, 1999). Exercise can also improve balance and co-ordination, strength and flexibility all of which decrease the risk of falls and hence the risk of fracture. Because of the varying degrees of osteoporosis and the risk of fracture certain flexibility exercises, strength training and weight bearing aerobic exercise may be unsuitable. Three types of exercise are recommended (CSP, 2001): 1) Flexibility exercises such as stretching to improve posture (Kelley G, 1998). These can help to reduce harmful stress on bones and maintain bone density. 2) Strength training including resistance training with weights (Kerr D, 1996). To be most effective these should be site specific, of sufficient intensity, progressive and low repetition. 3) Weight bearing aerobic exercises (Bassey EJ, 1995). Generally, in pre-menopausal women without a diagnosis of osteoporosis high impact exercise such as skipping, jogging and jumping has the greatest potential to improve BMD. For those not used to exercising and those over 50 years of age, low to medium impact exercise, such as step aerobics, intermittent jogging, brisk walking is more appropriate. In those patients with a diagnosis of osteoporosis stair climbing, low impact aerobics, line dancing, and Tai Chi will improve balance and strength. High impact exercises, high impact aerobics, sharp reflex actions e.g. squash, badminton and exercise which involves excessive forward bending should be avoided. These activities increase compression in the spine and lower extremities and can lead to fractures in weakened bones. Swimming and cycling are non-weight bearing exercises and therefore do not increase bone density. However, they improve fitness levels and joint mobility which allows weight bearing exercises to be performed more effectively. Worcestershire Acute Hospitals NHS Trust Page 8 of 35
9 GENERAL PRINCIPALS OF PRIMARY PREVENTION OF OSTEOPOROTIC FRAGILITY FRACTURES IN WOMEN 1. Follow the guidelines on page 6 Who to DEXA scan 2. Post-menopausal women fracture more in later years, independent of BMD values. This makes them more vulnerable to fracture from falling, particularly if they have recurrent falls. 3. Avoid treating young worried well (e.g. osteopenia) who have a low fracture probability as assessed by FRAX score use the FRAX tool ( 4. Borderline osteoporosis in the young needs to have their secondary causes identified and treated and consider referring to Secondary care. 5. Bisphosphonates are teratogenic and use in pre-menopausal women should be given with caution and counselling. 6. Bisphosphonates are licensed for use in men and women as a daily preparation. However, weekly preparations may be prescribed on an off-label use to improve compliance. 7. Osteopenic patients can be helped with life-style changes, unless 10 year fracture risk is high otherwise use the FRAX tool ( 8. If results OSTEOPOROTIC, discuss drug management, see table 3 below. 9. Advise that once treatment for osteoporosis is started it is likely that this will need to be continued. Table 3 Age Risk factors (see DEXA Scan result table 1 on page 6) (T score) 75 or older 2 or more (A or B) Not necessarily needed if scan unfeasible or not thought clinically appropriate. Action Drug treatment page or older 1 or more (A or B) or below Drug treatment page or more (1 must be from column B) or below Drug treatment page 10 Under 65 years 2 or more (1 each from columns A&B) or below Drug treatment page 10 Worcestershire Acute Hospitals NHS Trust Page 9 of 35
10 TREATMENT: DRUG THERAPIES PRIMARY PREVENTION OF OSTEOPOROTIC FRAGILITY FRACTURES IN WOMEN (Drug therapy to prevent fragility fractures in at risk patients) The FRAX tool ( can also help identify patients at high risk of fractures who should be given drug therapy to prevent fragility fractures. As discussed above (Who to DEXA scan? page 5) See clinical risk factors above, when identifying patients at a high risk of fractures. WHICH DRUG: First line: -Generic oral alendronate 10mg daily Consider prescribing 70mg once weekly preparation to encourage compliance (although not licensed for primary prevention) Second-line: -Risedronate orally 5mg daily. (Consider using 35mg once weekly to encourage compliance although not licensed for primary prevention) -Disodium etidronate orally as Didronel PMO These should be used when the patient has a contraindication to or intolerance of Alendronate or be unable to comply with the special instructions for its administration (See What factors affect choice of treatment? On page 14) AND also have a combination of T-Score, age and number of independent clinical risk factors as shown in the following table: Table 4 Number of independent clinical risk factors (Table 1 column B) Age X or older (X - treatment with Risedronate or Etidronate is not recommended) Third-line or if intolerant of bisphosphonates or contra-indicated : Strontium ranelate OR Denosumab: Strontium or Denosumab should be used when the patient has a contraindication to or intolerance of bisphosphonates or are unable to comply with the special instructions for their administration (See What factors affect choice of treatment? On page 16) AND also have a combination of T-Score, age and number of independent clinical risk factors as shown in the following table: Table 5 Number of independent clinical risk factors (Table 1 column B) Age X or older (X treatment with Strontium or Denosumab is not recommended) -Strontium ranelate 2g sachet at night. Falsely increases bone density, up to 50%, hence BMD reading subsequently not reliable. Current NICE guidelines (TA160 October 2008) recommend Strontium as a treatment option for the primary prevention of osteoporotic fractures in postmenopausal women at increased risk of fractures in the circumstances above. Worcestershire Acute Hospitals NHS Trust Page 10 of 35
11 -Denosumab Injection 60mg administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or back of arm. Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line by recombinant DNA technology. Current NICE guidelines (TA204 October 2010) recommend Denosumab as a treatment option for the primary prevention of osteoporotic fractures in postmenopausal women at increased risk of fractures in the circumstances above. See also Worcestershire Area Prescribing Committee. Guidelines for initiating treatment with Denosumab. August See Appendix 9. Worcestershire Acute Hospitals NHS Trust Page 11 of 35
12 SECONDARY TREATMENT/PREVENTION OF OSTEOPOROTIC FRAGILITY FRACTURES IN WOMEN Guidance for secondary prevention of fragility fractures in postmenopausal women who have osteoporosis and have sustained a clinically apparent osteoporotic fragility fracture. Table 6 Age DEXA Scan result Action (T score) 75 or older Not needed Drug treatment see below Under or below Drug treatment see below Notes Age 75 years or older, no need for prior DEXA scanning if clinician considers clinically inappropriate or unfeasible. Women who have had 2+ vertebral fractures treatment may be started while waiting for a DEXA scan. The National Orthopaedic Guideline Group (NOGG) recommend that women with a prior fragility fracture should be considered for treatment without the need for further risk assessment, although BMD measurement may sometimes be appropriate, particularly in younger postmenopausal women. This may result in more women receiving treatment than what NICE guidelines recommend and each case should be considered using all assessment models available and a decision reached between patient and clinician. Further advice is available from the Rheumatologists, Care of the Elderly team, Endocrinologists or Osteoporosis specialist nurse (appendix 8 referral form) in secondary care. Please see appendices 1, 2 and 3 for other patient groups. Osteoporotic fragility fracture is a fracture sustained as a result of a force equivalent to the force of a fall from a height equal to, or less than, that of an ordinary chair. WHICH DRUG: First-line - Generic oral alendronate 70mg weekly. (10mg daily licensed for osteoporosis in men, 5mg daily licensed for treatment of corticosteroid induced osteoporosis, 10mg daily licensed for corticosteroid induced osteoporosis in postmenopausal women not taking HRT however prescribers may wish to consider 70mg weekly preparation for off-license use on a named patient basis to improve patient compliance.) Second-line -Risedronate orally 35mg weekly. -Disodium etidronate orally as Didronel PMO Recommended as alternative treatment when the patient cannot comply with the special instructions for the administration of Alendronate or have a contraindication to or are intolerant of Alendronate. Third-line or if intolerant of bisphosphonates or contra-indicated : - Strontium ranelate orally or Denosumab injection -Strontium ranelate 2g sachet at night. Falsely increases bone density, up to 50%, hence BMD reading subsequently not reliable. Strontium should be used when the patient has a contraindication to or intolerance of bisphosphonates or is unable to comply with the special instructions for their administration (See What factors affect choice of treatment? On page 16), or in women who have had an unsatisfactory response to bisphosphonates defined as when the patient has had another fragility fracture despite adhering fully to treatment Worcestershire Acute Hospitals NHS Trust Page 12 of 35
13 for 1 year and there is evidence of a decline in BMD below their pre-treatment baseline if measured AND also have a combination of T-Score, age and number of independent clinical risk factors as shown in the following table: Table 7 Number of independent clinical risk factors (Table 1 column B) Age X or older (X treatment with Strontium is not recommended) Patients should advised to stop treatment if a skin rash occurs as this can be the first sign of a severe allergic reaction (DRESS see BNF or product literature - Denosumab 60mg Injection administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or back of arm. Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line by recombinant DNA technology. Denosumab should only be considered as a treatment option in patients who are unable to comply with the special instructions for administering Bisphosphonates, or have an intolerance of, or a contraindication to Bisphosphonates. See also Worcestershire Area Prescribing Committee. Guidelines for initiating treatment with Denosumab. August See Appendix 9. If both bisphosphonates, strontium ranelate and denosumab cannot be taken, alternatives are: Raloxifene 60mg Daily Teriparatide - 20micrograms once daily by subcutaneous injection for a maximum of 18 months. - Should be initiated and prescribed by specialists. - Should only be considered if patients who: Are unable to take a bisphosphonate (e.g.poor compliance, intolerance, contraindication.) Have a contraindication to, or are intolerant of Strontium. Have had an unsatisfactory response to bisphosphonates or Strontium (defined when a patient has another fragility fracture despite adhering fully to treatment for 1 year and there is evidence of a decline in BMD below their pre-treatment baseline.) Worcestershire Acute Hospitals NHS Trust Page 13 of 35
14 And: Table 8 Age N o fractures DEXA scan result (T-score) Action 65 or older or below Consider Teriparatide 65 or older or below Consider Teriparatide or below Consider Teriparatide Intranasal calcitonin. (Licensed for the treatment of postmenopausal osteoporosis to reduce risk of vertebral fractures.) Hormone replacement therapy-hrt. The CSM has advised that HRT should not be considered first-line therapy for the long-term prevention of osteoporosis in women over 50 years of age. HRT is of most benefit for the prophylaxis of postmenopausal osteoporosis if started early in menopause and continued for up to 5 years, but bone loss resumes (possibly at an accelerated rate) on stopping HRT. It should only be considered if other therapies are contraindicated, cannot be tolerated, or if there is a lack of response. Discuss the risks versus benefits before prescribing (for prescriptions see the CKS topic on Menopause). More information on cautions, contraindications and side-effects can be found in the current BNF. Worcestershire Acute Hospitals NHS Trust Page 14 of 35
15 Cautions, relative and absolute contraindications that affect choice of treatment: This list is not exhaustive and prescribers should ensure they are aware of specific cautions and contraindications for each drug they prescribe. Information can be found in the current BNF which can be accessed via or in the manufacturers summaries of product characteristics which can be accessed via Oesophageal stricture or achalasia / current or recent history of other upper gastrointestinal disorders: Do not use alendronate, try risedronate (but monitor closely for adverse effects). Oesophageal reactions: Severe oesophageal reactions have been reported with all oral bisphosphonates: patients should be advised to stop tablets and seek medical attention for symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain or heartburn. Other contraindications for bisphosphonates are: o o o Pregnancy, breast feeding. Hypocalcaemia must be corrected before starting treatment and then serum calcium concentrations monitored during treatment. Severe renal impairment (see paragraph below) When using bisphosphonates, balance the drug s overall proven effectiveness profile against tolerability and adverse effects in individual patients. NOGG have produced a tabular guide showing the main drug therapies evaluated effect on fracture risk. Venous thrombosis (active or past history): avoid raloxifene, strontium ranelate and hormone replacement therapy. Endometrial cancer, unexplained vaginal bleeding, or breast cancer: do not use raloxifene or hormone replacement therapy. Osteonecrosis of the jaw: Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelitis) has been reported in patients with cancer receiving treatment regimens including bisphosphonates administered intravenously or Denosumab injection. Many of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates and Denosumab in patients with concomitant risk factors (e.g. cancer, chemotherapy, radiotherapy, corticosteroids, poor oral hygiene). This should be carried out in Primary Care. While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate or Denosumab therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw but the bisphosphonates have long half-lives in bone which may suggest that discontinuation will have no added value. ( ( Severe renal impairment: Obtain specialist advice from a renal specialist team if appropriate. Current advice regarding suitability and dosing in patients with renal Worcestershire Acute Hospitals NHS Trust Page 15 of 35
16 impairment can be found in the current BNF ( or in the manufacturer s summaries of product characteristics. ( - Alendronate Avoid if egfr less than 35ml/min/1.73m 2 - Risedronate Avoid if egfr less than 30ml/min/1.73m 2 - Etidronate Avoid if egfr less than 20ml/min/1.73m 2 - Raloxifene Avoid if egfr less than 10ml/min/1.73m 2 - Strontium Avoid if egfr less than 30ml/min/1.73m 2 - Denosumab greater risk of developing hypocalcaemia if CrCl less than 30ml/min or receiving dialysis. Manufacturers advise monitoring plasma calcium concentrations. Other factors that affect choice of treatment: Compliance: Bisphosphonates have very specific administration requirements (see counselling points under each drug in the current BNF). Prescribers must ensure that the patient will comply with these instructions. Weekly preparations may increase compliance with some patients. Special consideration needs to be given to patients who have drugs administered by carers, especially on home visits, as they may not be able to supervise the patient for an adequate amount of time to ensure all the counselling points are followed. An unsatisfactory response = another fragility fracture despite adhering fully to treatment for 1 year and there is also evidence of a decline in BMD below her pretreatment baseline. Intolerance of oral bisphosphonates is defined as persistant upper gastrointestinal disturbance that is sufficiently severe to warrant discontinuation of treatment, and that occurs even though the instructions for administration have been followed correctly. (NICE TA161) Intolerance of Strontium ranelate is defined as persistent nausea or diarrhoea, either of which warrants discontinuation of treatment. (NICE TA161) Worcestershire Acute Hospitals NHS Trust Page 16 of 35
17 MEN WITH OSTEOPOROSIS Not currently covered by NICE guidelines. NOGG have produced guidelines for men over the age of 50. ( What: Lifestyle advice on dietary calcium and vitamin D intake, exercise, stopping smoking and reducing alcohol intake. (see also section above page 8) Assess the risk of falls, particularly in the elderly. All men should be investigated for hypogonadism. Exclude secondary causes of osteoporosis by performing the following investigations: o Testosterone, gonadotrophins (FSH, LH, and SHBG) to exclude hypogonadism o FBC, ESR, CRP o If ESR raised, check serum and urine electrophoresis to exclude multiple myeloma o o o o Bone, liver, and renal biochemistry, to exclude osteomalacia, other metabolic causes of osteoporosis, and renal osteodystrophy TFTs, to exclude hyperthyroidism Bone profile including calcium, alkaline phosphate and vitamin D3 levels Men on LHRH analogues treatment for prostatic cancers. A 10-year risk of fracture model has been developed to identify those at highest risk. The FRAX tool ( computes the 10-year probability of hip fracture or a major osteoporotic fracture using a patient s clinical risk factors with or without bone mineral density results. (Nb the tool does not currently include falls in the algorithm and a falls risk assessment should also be carried out) o o If access is available to use the FRAX model, follow their assessment tool for each individual patient. If access to the FRAX model is not available, the following algorithm from the NOGG guidelines can be used: The charts below give average 10 year fracture probabilities according to age, BMI and the number of risk factors. The chart is colour coded. Green denotes that an individual s risk lies below the intervention threshold i.e. treatment is not indicated. Red denotes that the fracture probability is consistently above the upper assessment threshold, irrespective of the mix of risk factors, so that treatment can generally be strongly recommended. The intermediate category (yellow) denotes that probabilities lie between these limits and that a BMD test should be considered to improve the estimate of fracture risk. Assessment of men with or without previous fracture according to body mass index (BMI) and the number of risk factors (as shown in table 1) Table 1 (modified for men) Indicators of low BMD (column A) Independent clinical risk factors for fracture (column B) Low body mass index (BMI 22kg/m 2 or less) Rheumatoid Arthritis Parental history of hip fracture Prolonged Immobilisation Alcohol intake of 4 units or more daily Ankylosing spondylitis Crohn s disease (see appendix 2) Worcestershire Acute Hospitals NHS Trust Page 17 of 35
18 Age 50 N o risk factors (as in table 1) BMI Age 60 N o risk factors (as in table 1) BMI Age 70 N o risk factors (as in table 1) BMI Age 80 N o risk factors (as in table 1) BMI Reassure. Advise lifestyle changes Consider DEXA scan Consider treatment +/- DEXA scan If/when DEXA scan results are available: In men in whom BMD is available at the femoral neck, 10 year fracture probability can be approximated according to age, BMD T-score and the number of risk factors. The chart below is colour coded. Green denotes that an individual s risk lies below the intervention threshold i.e. treatment is not indicated. Red denotes that the fracture probability is consistently above the upper assessment threshold, irrespective of the mix of risk factors, so that treatment can be strongly recommended in most cases. The intermediate category (yellow) denotes that probabilities lie between these limits and that treatment can be recommended in those with the stronger risk factors. Assessment of men with or without previous fracture according to femoral neck T- score for BMD and risk factors as shown in table 1 Table 1 (modified for men) Indicators of low BMD (column A) Independent clinical risk factors for fracture (column B) Low body mass index (BMI 22kg/m 2 or less) Prolonged Immobilisation Ankylosing spondylitis Crohn s disease (see appendix 2) Rheumatoid Arthritis Parental history of hip fracture Alcohol intake of 4 units or more daily Worcestershire Acute Hospitals NHS Trust Page 18 of 35
19 Age 50 N o risk factors (as in table 1) BMD Age 60 N o risk factors (as in table 1) BMD Age 70 N o risk factors (as in table 1) BMD Age 80 N o risk factors (as in table 1) BMI Reassure. Advise lifestyle changes Consider treatment Strongly recommend treatment Consider referring all men with osteoporosis for specialist assessment and advice on treatment. Treatment in men is best initiated after specialist assessment. However, if there is likely to be considerable delay before seeing a specialist, it may be appropriate to start drug treatment. Treat with Alendronate and give calcium + vitamin D if dietary intake is low. Seek specialist advice for other treatment options if Alendronate is contraindicated or not tolerated. Bisphosphonates are licensed in men consider weekly preparations to improve compliance as above. Drug therapies licensed for use in men are: o o Alendronate Risedronate See above for usual doses used (page 10) Worcestershire Acute Hospitals NHS Trust Page 19 of 35
20 OUTCOME MEASURES following treatment for osteoporosis: Reduction in the number of fractures, particularly vertebral, hip, and other axial skeleton fractures. Reduction in the number of deaths following fractured femur. The proportion of people with a history of osteoporotic fragility fracture who are taking bone-protective treatment. MONITORING TOOL How will monitoring be carried out? Who will monitor compliance with the guideline? Clinical audit Secondary care pharmacy department, reporting to Medicines Safety Committee. (to monitor prescribing compliance) Clinical Governance primary and secondary care. Other groups as deemed appropriate. Standards as detailed in NICE guidance. Worcestershire Acute Hospitals NHS Trust Page 20 of 35
21 REFERENCES NICE TA87 Technology Appraisal Guidance 87 Bisophosphonates, selective oestrogen receptor modulators and parathyroid hormone for the second prevention of osteoporosis fragility fractures in postmenopausal women, January NOTE Now re-appraised as NICE TA161 see below. NICE TA160 technology appraisal guidance 160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. October NICE TA161 technology appraisal guidance 161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. October Hillner et al. Clin Oncol 2003 ; 21 : BSG Guidelines for osteoporosis in inflammatory bowel disease and eliac disease June Clinical Knowledge Summaries Service (CKS) guidelines Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. National Osteoporosis Guideline Group. (accessed 20/11/08) FRAX tool for the assessment of fracture risk. National Osteoporosis Guideline Group. (accessed 20/11/08 ) British National Formulary (BNF). Number 61. Published by BMJ group and RPS publishing, Bedfordshire, UK. March ( accessed 6/09/2011 Worcestershire Area Prescribing Committee. Guidelines for initiating treatment with Denosumab. August NICE TA204 Technology Appraisal Guidance 204.Denosumab for the prevention of osteoporotic fractures in postmenopausal women. October Worcestershire County Area Prescribing Committee. Guidelines for the use of calcium and vitamin D in falls prevention in adults. April 2012 Worcestershire Acute Hospitals NHS Trust Page 21 of 35
22 APPENDIX 1 BREAST CANCER PATIENTS Breast Cancer Patients EFFECT OF TAMOXIFEN ON BONES: Pre-menopausal women: Post-menopausal women: Hip and Spine BMD No fractures in chemo-prevention trials BMD Hip and Spine at 1 year BMD at both sites at 3 years (about 4%) fracture-risk in chemo-prevention trials EFFECT OF AROMATASE-INHIBITORS ON BONES: Pre-menopausal women: Post-menopausal women: Prevents peripheral aromatization of androgen oestradiol. Not used in premenopausal women fracture-risk with anastrozole and letrozole. Exemestane BMD loss at hip and spine SUGGESTED MANAGEMENT: Low Risk: High Risk: Life style changes Calcium and Vitamin D supplements Monitor ANNUALLY for risk status CLINICALLY 65 years of age or older Aromatase therapy Women changing from Tamoxifen to Aromatase therapy Women undergoing Chemotherapy When the RESULTS are: Do BASELINE DEXA for hip and spine 1. NORMAL Suggest life-style changes; Calcium + Vitamin D 3-yearly DEXA scans 2. OSTEOPENIA As above, EXCEPT when Aromatase Therapy started commence Bisphosphonates 3. OSTEOPOROSIS Suggest life-style changes; Calcium + Vitamin D Bisphosphonates (NB Teratogenic properties) OR Raloxifene (but NOT when Aromatase Therapy in progress) ANNUAL DEXA scans. (Ref: from Hillner et al. Clin Oncol 2003; 21: ) Worcestershire Acute Hospitals NHS Trust Page 22 of 35
23 APPENDIX 2 BOWEL DISEASE PATIENTS Inflammatory Bowel and Coeliac Disease Inflammatory Bowel Disease and Coeliac Disease are associated with increased risk of osteoporosis. Relative risk for all fractures is: 1:1.3 for Crohn s Disease 1:1.2 for Ulcerative Colitis 1:1.4 for Coeliac Disease General Recommendations Regular weight bearing exercise Balanced diet Dietary calcium intake ( up to 1200 mg daily) Treat Vitamin D deficiency ( Check ALP, Calcium and PTH) Avoid excess alcohol and smoking. Specific Measures for Inflammatory Bowel Disease Consider elemental or polymeric diet for Crohn s disease before steroids Early use of azathioprine / 6 MP. Steroid avoidance Consider budesonide instead of prednisolone for small bowel or ileo-caecal Crohn s disease. Budesonide is a glucocorticosteroid with a high local antiinflammatory effect. At doses clinically equivalent to systemically acting glucocorticosteroids, budesonide gives significantly less HPA axis suppression. It causes fewer systemic side-effects than oral prednisolone but may be less effective.( ) Use steroids at the lowest effective dose and shortest effective duration Consider biological treatment if steroid remission is not achieved. For those on steroids: Age 65 or older: consider bisphosphonates on starting steroids Age under 65 years old: at high risk and requiring steroids (any dose) more than 3 months: DEXA and consider bisphosophonates if T score < -1.5 SD Give Vitamin D and Calcium DEXA Scan for those at higher risk of osteoporosis e.g. 2 or more of Continuing active disease Age 70 years or older Weight loss of more than 10% BMI less than 20 Specific Measures for Coeliac Disease General recommendations as above. DEXA scan for those at high risk Gluten-free diet Indications for DEXA Scan Persisting symptoms on gluten free diet for 1 year weight loss more than 10 % BMI less than 20 Age 70 or older Treatment of osteoporosis (see also notes in main guideline) Worcestershire Acute Hospitals NHS Trust Page 23 of 35
24 If low T score on DEXA + risk factors OR prior fragility fracture: Oral bisphosphonates, long term Intolerance or failure of bisphosphonates in postmenopausal women or men over 55 consider: Raloxifene ( only) Teriparatide daily injection for 18 months Calcitonin by intranasal spray Men with low BMD: Consider hypogonadism check blood testosterone and replace if low. Follow up DEXA scans For high risk patients on high dose steroid therapy Repeat DEXA for every subsequent year of steroid use until intervention threshold (T score of -1.5 is reached). Reference: BSG Guidelines for osteoporosis in inflammatory bowel disease and Coeliac disease June Worcestershire Acute Hospitals NHS Trust Page 24 of 35
25 APPENDIX 3 CORTICOSTEROID THERAPY CORTICOSTEROID THERAPY (Based on Clinical Knowledge Summaries Service (CKS) guidelines) Rate of corticosteroid use - 1% adult population to 2.4% (age years) Corticosteroids cause significant fracture risk to hips and spines. Fractures seen at doses less than 7.5mg/day. High-dose inhaled steroids may also cause bone loss in some, as can low-dose chronic therapy. The greatest rate of bone loss occurs during the first 6-12 months of corticosteroid. Effect of corticosteroids tends to increase fracture-risk greater than with just the falling BMD. Risk of fracture is enhanced in this group. Fracture-risk assessment in this group recommended, using DEXA scanning. Recommended measures are: 1. Reduce dose of corticosteroids, where possible. 2. Consider use of alternative formulations. 3. Consider alternative immune-suppressive agents. 4. Encourage good nutrition, adequate calcium intake and physical activity. 5. Suggest tobacco and alcohol abuse reduction. Studies show beneficial effects on BMD with medications. REDUCTION IN VERTEBRAL FRACTURES observed during safety analysis on most of present-day bisphosphonates in use. TREATMENT OF STEROID-INDUCED OSTEOPOROSIS High-risk groups on corticosteroid therapy are: years old or older 2. Age 40 years or older, with previous fragility fractures (CAUTION: bisphosphonates teratogenic) - COMMENCE bone protection regime at the time of starting corticosteroids. For OTHERS: Appendix 5 - DEXA scan when corticosteroids to be used for more than 3 months (Consider commencing treatment when T score -1.5 SD or less). - Consider repeat DEXA 2 years after therapy commenced to check BMD. Worcestershire Acute Hospitals NHS Trust Page 25 of 35
26 APPENDIX 4A LEVEL 1 REFERRAL FORM FALLS ASSESSMENT (SEE NEXT PAGE) Worcestershire Acute Hospitals NHS Trust Page 26 of 35
27 FALLS RISK CASE FINDING TOOL Level 1 Level 1 Falls screening to be performed by any Health, Mental Health Team, Adult Community Services, Home Care Teams, A&E, MIU,Ambulance staff and Voluntary or Independent Sector setting. (Tool based on the falls risk assessment Tool - FRAT and has been adapted for local use) Name: Date of Birth NHS No. (if known): Address: Phone Number: Carer Contact Details / first point of contact if appropriate GP and Surgery: Name: Telephone: Please use, Guidance Notes and Agreed Action Plan overleaf before completing this form YES 1 Is there a history of any fall in the previous year? Number of falls in past 12 months. Approximate date of last fall 2 Is the person on four or more different medications per day? Has the person had a recent change in medication? - please circle: yes or no Has the person had a recent medication review? - please circle: yes or no Which chemist do you get your medicines from? - insert details in comments box below 3 Does the person have a diagnosis of stroke or Parkinson s disease? 4 Does the person have any problems with their balance? 5 Is the person unable to stand up from a chair of knee height without pushing up with their arms and hands? NO If the person has fallen, do they complain of blackouts, loss of consciousness? CONSENT: I am willing to have a further falls risk assessment if necessary. This may involve a referral to another member of the health care team. Verbal consent gained Yes No The details of this assessment will be added to the Central Falls Register held by the PCT. Verbal consent gained Yes No The assessor will give Falls Prevention advice and provide general Falls and Health and Well Being information. Tick Leaflet given 6. Comments: eg: form completed with carer. If form completed by OT/PT please circle OT /PT Assessment completed and intervention actioned Send all Level 1 screening tools to: Falls Prevention Coordinator: Training and Development Centre,Evesham Community Hospital, Waterside WR11 1JT TEL No / FAX no wor-pct.falls-prevention@nhs.net Name of Assessor: Designation: Organisation: Signature: Date: Tel: Fallslevelonecasefindingtoolrevised April 2011
28 Guidance notes to assist completing the stage 1 screening tool 1. How assessed? Ask the person/carer if they have fallen in the last twelve months and the number of falls in the last twelve months (please note the number of falls in the space provided) If the person had 1 or more falls in the last twelve months, place a tick in the YES column. 2. How assessed? Identify the number of different type of medications the person is taking per day. 3. (This includes prescribed and unprescribed medication) If the person takes four or more different type of medications, place a tick in the YES column. Please circle if any recent change in medication and please circle if there has not been a medication review. Please insert which chemist/address that dispenses their medication in comments box. 4. How assessed? Ask the person/carer if they have been diagnosed with a stroke or Parkinson s disease? If yes, place a tick in the YES column. 5. How assessed? Ask the person/carer if they feel unsteady when standing and/or whilst walking? If yes, place a tick in the YES column. Another way to find out if they have problems with their balance is to ask the person a question while the person is walking. Keep walking while you do so. If the person stops walking immediately or as soon as they start to answer they are at higher risk of falling and place a tick in the YES column. If there is a sway (i.e the person raises their arms or takes another step to maintain balance) in standing, place a tick in the YES column 6. How assessed? Ask the person to stand up from a standard height chair (ie. The seat is at knee height) without using their arms to assist to stand up? If they are unable to stand up without using their arms to assist, place a tick in the YES column. 7. Consent: Mental Capacity: A person must be assumed to have capacity unless it is established that he/she lacks capacity A person is not to be treated as unable to make a decision unless all practical steps to help them to do so have been taken without success A person is not to be treated as unable to make a decision merely because they make an unwise decision Anything done for or on behalf of a person who lacks mental capacity must be done in their best interests Anything done for, or on behalf of, people without capacity should be the least restrictive of their basic rights and freedoms 8. Use of Comments Box: Please indicate whether the form was completed with the help of a carer. Complete carer s details as appropriate. Also use for additional information that will be helpful/useful for future management. If patient has a history of dementia/neurological problems/palliative care needs. Name & Address of chemist where their medication is dispensed. NB Standard Falls and Health and Wellbeing Information to be given by the assessor to all who have a level 1 screening undertaken. The following leaflet should be obtained (free of charge) from Age UK head office Tel: Staying Steady: Improving Your Strength and Balance(AgeUKIG14) AGREED ACTION PLAN AND REFERRAL PROCESS: Score 2 yes responses:- If the person has fallen and is on four or more medications, has HAD a recent change in medication and has NOT had a recent medication review - the falls prevention coordinator will refer to the community pharmacist. If the person has fallen and there is a problem with the persons strength or balance the falls prevention coordinator will Send information re local exercise activities. If there is a history of blackouts or unexplained falls, the falls prevention coordinator will inform the GP and the need for onward referral to a Level 3 specialist falls clinic will be considered. Score 3 or more yes responses: The Falls Prevention Coordinator will refer the person for a level 2 multi-factorial falls assessment. Fallslevelonecasefindingtoolrevised April 2011
Dumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 Multiple low trauma vertebral fractures in the absence of myeloma or metastatic disease. 2 T-score
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This guideline incorporates some of the recommendations from SIGN, NICE, National Group (NOGG) and local expert opinion. It adopts
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationBarts Health NHS Trust and local GPs Shared Care Guidelines. DENOSUMAB (Prolia) Post menopausal osteoporosis
Barts Health NHS Trust and local GPs Shared Care Guidelines Indication: DENOSUMAB (Prolia) Post menopausal osteoporosis DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationGuidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION should be recommended
Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION Denosumab is suitable for patients with established osteoporosis for both primary and secondary fracture prevention
More informationUnderstanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.
Understanding NICE guidance Information for people who use NHS services Alendronate, etidronate, risedronate, strontium ranelate and raloxifene for preventing bone fractures in postmenopausal women with
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationOsteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance
Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing
More informationGuidelines on Management of Osteoporosis
Guidelines on Management of Osteoporosis Introduction These guidelines take into account recommendations from the DH Guidance on Falls and Fractures (Jul 2009), NICE Technology appraisals for Primary and
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationInitial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above
Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above 2 or > vertebral fractures Low trauma fracture In past 5 years Risk Factors (table1)
More informationAdministration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures 2017 18 1. Purpose of Agreement This agreement outlines the expectations
More informationSCHEDULE 2 THE SERVICES. A. Service Specifications
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationGuidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals
WA.DRUG EVALUATION PANEL Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals Introduction Osteoporotic fracture-related hospitalisations impose a substantial financial
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationBisphosphonate treatment break
Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More information[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationOxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer
Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer Category: Summary: Guideline Adjuvant Bisphosphonate treatment for Post-Menopausal
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline the use of Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Author(s)/Originator(s):
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationBisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday
Bisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday This guidance incorporate National Osteoporosis Guideline Group (NOGG) guidance March 2017 Clinical guideline for
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More information3. Has bone specific alkaline phosphatase level increased OR does the member have symptoms related to active Paget s?
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA CCC PLUS and MEDALLIO/FAMIS 4.0 Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationNorth Central London Joint Formulary Committee
North Central London Joint Formulary Committee Calcium + vitamin D supplementation for the prevention of osteoporotic fragility fractures Disclaimer This guideline is registered at North Central London
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationDEXA SCAN POLICY CRITERIA BASED ACCESS
DEXA SCAN POLICY Version: 1718.v2 Recommendation by: Somerset CCG Clinical Commissioning Policy Forum (CCPF) Date Ratified: 01 November 2017 Name of Originator/Author: Approved by Responsible Committee/Individual:
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationThe recent publication of guidance from the National
216 Clinical Pharmacist May 2009 Vol 1 Several guidelines exist for the identification and treatment of osteoporosis. Patients diagnosed with the condition should be prescribed bisphosphonates, if suitable,
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464
Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationYou have been referred to the osteoporosis clinic because you have sustained a fracture of the *hip / vertebra / wrist.
EXAMPLE 1a FRACTURE PATIENT INVITE LETTER «ClinicPhone» «PatientAddress1» «PatientAddress2» «PatientAddress3» «PatientAddress4» «PatientPostcode» Dear «PatientTitle» «PatientSurname» You have been referred
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper Quality standard topic: Osteoporosis Output: Prioritised quality improvement
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationOsteoporosis. Information leaflet. This information is also available on request in other formats by phoning
Osteoporosis This information is also available on request in other formats by phoning 01387 241053. Information leaflet Produced by Katrina Martin (2007) Updated Mar. 2010 Review date 2013 Contents Page(s)
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464
Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationRecent advances in the management of osteoporosis
CONFERENCE SUMMARIES Clinical Medicine 2009, Vol 9, No 6: 565 9 Recent advances in the management of osteoporosis Juliet Compston Introduction Osteoporotic fractures are a major cause of morbidity and
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationQuality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture
Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Osteoporosis - fragility fracture Indicators NM29: The practice can produce a register of patients: 1. Aged
More informationCortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly
Osteoporosis POOLE, K.E.S. & COMPSTON, J.E. (2006): Osteoporosis and its management. BMJ 333:1251-6. Physiology Cortical bone After age 40, gradually decreases 0.3-0.5% yearly, in both men and women Postmenopausally,
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationAll about. Osteoporosis
All about Osteoporosis What is osteoporosis? Osteoporosis literally means porous bone. It is a condition that causes bones to become thin and fragile, decreasing bone strength and making them more prone
More informationIssue date: October Review date: July 2010
Issue date: October 2008 Review date: July 2010 Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationOsteoporosis. Definition
Osteoporosis Definition Osteoporosis causes bones to become weak and brittle so brittle that a fall or even mild stresses like bending over or coughing can cause a fracture. Osteoporosis-related fractures
More informationBone density scanning and osteoporosis
Bone density scanning and osteoporosis What is osteoporosis? Osteoporosis occurs when the struts which make up the mesh-like structure within bones become thin causing them to become fragile and break
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationMy joints ache. What is the difference between osteoporosis and osteoarthritis?
Osteoporosis What is osteoporosis? Osteoporosis means bones are less dense, more fragile, and at greater risk for breaking, even with small injuries. This problem often affects bones in the hip, spine,
More information